Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

Clinical trial NCT07100730 · RECRUITING

Trial details

NCT number: NCT07100730
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Neoplastic Disease Glioblastoma Glioblastoma (GBM)Glioblastoma Multiform Glioblastoma Multiforme, Adult Glioblastoma Multiforme (GBM) WHO Grade IV

Start date: 2025-11-02
Primary completion: 2027-07-01
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.